Smokeless Tobacco Users
This is the fastest growing segment of tobacco users. Over 12 million persons used some form of smokeless tobacco (chewing tobacco and snufl) in 1985, and approximately 6 million used smokeless tobacco weekly or more often. Use is increasing, particularly among young males. Not only does this habit lead to oral and pharyngeal cancer and gum disease, but also the potential addiction to nicotine may lead smokeless tobacco users to cigarette smoking. The goals of STCP research are to identify the patterns and major factors that influence the use of smokeless tobacco and to implement and evaluate intervention strategies to minimize its use. Several intervention research projects that are aimed at smokeless tobacco users will begin in fiscal year 1987. Five intervention trials are already under way through the STCP and 2 others will begin soon. In all, these trials will affect at least 37,000 people through assessment of smokeless tobacco use and delivery of prevention and cessation programs. Interventions will be delivered through schools, youth and community organizations, and dental health care offices. my canadian pharmacy.com
The STCP Strategy
NCI’s national program in smoking and tobacco use control utilizes the same scientific logic that is used for its national cancer control program (Fig 1). The logic in these programs emphasizes a progression of activity from basic investigations to broad applications in target populations through an orderly sequence of 5 phases:
Phase 1: Hypothesis development. A systematic review and synthesis of existing data and information lead to the development of hypotheses for smoking control intervention methodologies.
Phase 2: Methods development Intervention methods and research tools are developed and tested. Potential intervention methods are assessed for accuracy, validity, sensitivity, specificity, and cost-effectiveness.
Phase 3: Controlled intervention trials. Using the methods that are validated in phase 2, the efficacy of the intervention is tested on a group of individuals who may be selected to optimize the interpretation of efficacy.